Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Chimeric Therapeutics Ltd. has announced a change in the interests of its substantial holder, Paul Hopper, as of May 26, 2025. The voting power of Hopper’s fully paid ordinary shares has decreased from 12.4% to 10.2%, indicating a dilution in his stake due to a placement. This change reflects a strategic adjustment in shareholder interests, potentially impacting the company’s market positioning and stakeholder dynamics.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment. The company is listed on the Australian Securities Exchange under the ticker CHM.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.4M
For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.